What's the latest on vascepa's faster approval timeline?

What sped up Vascepa's approval process?

Vascepa received its initial FDA approval in 2012 solely for patients with very high triglyceride levels. A subsequent application for a broader cardiovascular risk reduction claim drew regular review cycles until the REDUCE-IT trial demonstrated a 25% relative risk reduction in major cardiovascular events. The FDA then granted priority review in 2019, shortening the standard 10-month review to 6 months. This decision reflected the agency's recognition of the trial's clinical significance and unmet medical need.

How long did the priority review take?

The priority review designation moved the agency's target date forward to December 28, 2019. The FDA approved the expanded label on December 13, 2019, ahead of its own target. The company announced the decision immediately after the agency reached it, which was five days before the calculated 6-month deadline.

Why did the FDA choose priority review?

Priority review is given to drugs that treat serious conditions and offer significant improvements over available therapies. The REDUCE-IT trial showed Vascepa reduced heart attacks, strokes, and cardiovascular death in patients with elevated triglycerides who were already on statins. The agency applied the designation because the data presented evidence of a real clinical benefit in a population that had limited options beyond lifestyle changes and statin therapy.

Can similar drugs follow the same timeline?

Similar drugs targeting triglyceride reduction or cardiovascular outcomes can petition for priority review if their pivotal trials show substantial clinical improvement. Many cardiovascular candidates still undergo standard 10-month cycles unless their data demonstrate strong statistical significance and large effect sizes.